LB Pharmaceuticals Inc LBRX R2K
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -25.2% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LBRX LB Pharmaceuticals Inc R2K | 27.97 | - | $802.09M | - | -9.95% | -19.56% | - | -25.22% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 6.43M | 4.86M | 5.25M | 13.87M | 22.10M |
| Operating Income | - | - | - | -6.43M | -4.86M | -5.25M | -13.87M | -22.10M |
| EBITDA | - | - | - | -6.35M | -4.78M | -5.17M | -13.79M | -22.02M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M |
| Tax Provision | - | - | - | 0 | 0 | 0 | 1.00K | 0 |
| Net Income | -16.22M | -27.63M | - | -5.31M | -4.87M | -3.56M | -11.47M | -19.05M |
| Diluted EPS | - | - | -4.01 | -0.24 | - | -0.61 | -0.45 | -0.67 |
| R&D Expense | - | - | 10.66M | 3.42M | - | 2.42M | - | 14.64M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.40M |
| Operating Income | -2.81M | -11.38M | -64.83M | -30.40M |
| EBITDA | -12.19M | -1.45M | -64.74M | -30.08M |
| Interest Expense | 2.15M | 4.83M | 0 | - |
| Pretax Income | -14.35M | -6.27M | -63.10M | -25.20M |
| Tax Provision | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -14.35M | -6.28M | -63.10M | -25.20M |
| Diluted EPS | -4.05 | -1.77 | -17.82 | -3.13 |
| R&D Expense | - | - | 51.17M | 16.74M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -25.22% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +61.68% |
| 6 Months: | +72.65% |
| 3 Months: | +16.49% |
| 1 Month: | -8.56% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 21.49M | 45.66M | 33.53M | 312.93M |
| Current Assets | 21.49M | 45.63M | 28.88M | 308.43M |
| Cash & Equivalents | 21.40M | 14.98M | 22.98M | 250.17M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 50.30M | 80.13M | 128.09M | 11.62M |
| Current Liabilities | 469.00K | 2.61M | 8.11M | 7.44M |
| Long Term Debt | 24.15M | - | - | - |
| Total Debt | 24.15M | 0 | 3.70M | 3.57M |
| Total Equity | -28.81M | -34.47M | -94.55M | 301.31M |
| Shares Outstanding | 22.44M | 22.44M | 22.44M | 25.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -2.73M | -12.09M | -53.05M | -35.21M |
| Investing Cash Flow | 123.00K | -28.01M | 23.23M | -39.89M |
| Financing Cash Flow | 22.96M | 33.68M | 38.31M | 302.56M |
| Capital Expenditure | - | -25.00K | -769.00K | -52.00K |
| Free Cash Flow | -2.73M | -12.12M | -53.82M | -35.26M |
| Net Change in Cash | 20.36M | -6.42M | 8.50M | 227.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 49.8% | 18.2% | 66.7% | -8.4% |
| ROCE % | -13.4% | -26.4% | -255.0% | -10.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Deep Track Capital, Lp | 11.69% | 3.35M | $93.78M |
| 2 | Blackrock Inc. | 8.62% | 2.47M | $69.11M |
| 3 | RA Capital Management, L.P. | 7.70% | 2.21M | $61.77M |
| 4 | TCG Crossover Management, LLC | 6.41% | 1.84M | $51.45M |
| 5 | Commodore Capital Lp | 5.23% | 1.50M | $41.95M |
| 6 | Caligan Partners, LP | 5.01% | 1.44M | $40.22M |
| 7 | JPMORGAN CHASE & CO | 4.98% | 1.43M | $39.93M |
| 8 | Spruce Street Capital LP | 4.80% | 1.38M | $38.49M |
| 9 | Trails Edge Capital Partners, LP | 4.60% | 1.32M | $36.90M |
| 10 | Nantahala Capital Management, LLC | 3.67% | 1.05M | $29.45M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LBRX